RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCIE SCOPUS

      Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia

      한글로보기

      https://www.riss.kr/link?id=A106663752

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Purpose The presentations and geographic incidence of pediatric non-Hodgkin lymphoma (NHL) differ from those of adults. This study delineated the characteristics and outcomes of pediatric NHL in East Asia. Materials and Methods Medical records of 749...

      Purpose The presentations and geographic incidence of pediatric non-Hodgkin lymphoma (NHL) differ from those of adults. This study delineated the characteristics and outcomes of pediatric NHL in East Asia.
      Materials and Methods Medical records of 749 pediatric patients with NHL treated at participating institutions in mainland China, Japan, Korea, and Taiwan from January 2008 to December 2013 were reviewed. Demographic and clinical features, survival outcomes, and putative prognostic factors were analyzed.
      Results Five hundred thirty patients (71%) were male. The most common pathologic subtypes were Burkitt lymphoma (BL) (36%). Six hundred seven patients (81%) had advanced diseases at diagnosis. The 5-year overall survival and event-free survival (EFS) rates were 89% and 84%.
      The 5-year EFS rates of BL, lymphoblastic lymphoma, and diffuse large B-cell lymphoma were 88%, 88%, and 89%, and those of anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) were 71% and 56% (p < 0.001). Central nervous system involvement, high lactate dehydrogenase level (> 250 IU/mL), and advanced disease at diagnosis ( stage III) were associated with poor outcomes (p < 0.05). ALCL and PTCL relapsed more frequently than other pathologic subtypes (p < 0.001).
      Conclusion In East Asia, PTCL was more frequent than in Western countries, and bone marrow involvement did not affect treatment outcome. This international study should motivate future collaborative study on NHL in East Asia.

      더보기

      참고문헌 (Reference)

      1 Sabattini E, "WHO classification of tumours of haematopoietic and lymphoid tissues in 2008 : an overview" 102 : 83-87, 2010

      2 Pishko A, "The role of novel immunotherapies in non-Hodgkin lymphoma" 6 : 93-103, 2017

      3 Burkhardt B, "The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence" 131 : 39-49, 2005

      4 Topp MS, "Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia : a multicentre, single-arm, phase 2 study" 16 : 57-66, 2015

      5 Patte C, "Results of the randomized international FAB/LMB96trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents : it is possible to reduce treatment for the early responding patients" 109 : 2773-2780, 2007

      6 Cairo MS, "Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents" 109 : 2736-2743, 2007

      7 Mitsui T, "Recent progress in the treatment of pediatric lymphoma in Japan" 58 : 2168-2177, 2017

      8 Le Deley MC, "Prognostic factors in childhood anaplastic large cell lymphoma : results of a large European intergroup study" 111 : 1560-1566, 2008

      9 Burkhardt B, "Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma : a report from the berlin-frankfurt-muenster group" 27 : 3363-3369, 2009

      10 Batlevi CL, "Novel immunotherapies in lymphoid malignancies" 13 : 25-40, 2016

      1 Sabattini E, "WHO classification of tumours of haematopoietic and lymphoid tissues in 2008 : an overview" 102 : 83-87, 2010

      2 Pishko A, "The role of novel immunotherapies in non-Hodgkin lymphoma" 6 : 93-103, 2017

      3 Burkhardt B, "The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence" 131 : 39-49, 2005

      4 Topp MS, "Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia : a multicentre, single-arm, phase 2 study" 16 : 57-66, 2015

      5 Patte C, "Results of the randomized international FAB/LMB96trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents : it is possible to reduce treatment for the early responding patients" 109 : 2773-2780, 2007

      6 Cairo MS, "Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents" 109 : 2736-2743, 2007

      7 Mitsui T, "Recent progress in the treatment of pediatric lymphoma in Japan" 58 : 2168-2177, 2017

      8 Le Deley MC, "Prognostic factors in childhood anaplastic large cell lymphoma : results of a large European intergroup study" 111 : 1560-1566, 2008

      9 Burkhardt B, "Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma : a report from the berlin-frankfurt-muenster group" 27 : 3363-3369, 2009

      10 Batlevi CL, "Novel immunotherapies in lymphoid malignancies" 13 : 25-40, 2016

      11 Kontny U, "Non-anaplastic peripheral T-cell lymphoma in children and adolescents : a retrospective analysis of the NHL-BFM study group" 168 : 835-844, 2015

      12 Reiter A, "Non-Hodgkin's lymphomas of childhood and adolescence : results of a treatment stratified for biologic subtypes and stage : a report of the Berlin-Frankfurt-Munster Group" 13 : 359-372, 1995

      13 Minard-Colin V, "Non-Hodgkin lymphoma in children and adolescents : progress through effective collaboration, current knowledge, and challenges ahead" 33 : 2963-2974, 2015

      14 Mussolin L, "Minimal disseminated disease in high-risk Burkitt's lymphoma identifies patients with different prognosis" 29 : 1779-1784, 2011

      15 Coustan-Smith E, "Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma : a report from the children's oncology group" 27 : 3533-3539, 2009

      16 Shiramizu B, "Minimal disease assessment in the treatment of children and adolescents with intermediate-risk(Stage III/IV)B-cell non-Hodgkin lymphoma : a children's oncology group report" 153 : 758-763, 2011

      17 Cairo MS, "Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate('Orange')in children with advanced non-lymphoblastic non-Hodgkin's lymphoma : a children's cancer group report" 16 : 594-600, 2002

      18 Vose J, "International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes" 26 : 4124-4130, 2008

      19 Marky I, "Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement : a 6-year population-based study from the nordic society of pediatric hematology and oncology" 26 : 555-560, 2004

      20 Reiter A, "Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma : a BFM group report" 95 : 416-421, 2000

      21 Reiter A, "Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy : a report of the Berlin-Frankfurt-Munster Group Trial NHLBFM 90" 94 : 3294-3306, 1999

      22 Anderson JR, "Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project" 9 : 717-720, 1998

      23 Hwang IG, "Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea : comparison of Korean all-ages group and Western younger age group" 7 : 580-586, 2007

      24 김혜리, "Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents" 대한암학회 46 (46): 358-365, 2014

      25 Murphy SB, "Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas : dissimilarities from lymphomas in adults" 7 : 332-339, 1980

      26 Brugieres L, "CD30(+)anaplastic large-cell lymphoma in children : analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology" 92 : 3591-3598, 1998

      27 Williams DM, "Anaplastic large cell lymphoma in childhood : analysis of 72 patients treated on the United Kingdom Children's Cancer Study Group chemotherapy regimens" 117 : 812-820, 2002

      28 Cairo MS, "Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age(≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma : results of the FAB LMB 96 study" 30 : 387-393, 2012

      29 Hochberg J, "Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma : state of the science" 144 : 24-40, 2009

      30 Lymphoma Study Group, Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association, "A collaborative study of children with lymphoblastic non-Hodgkin's lymphoma in China" 53 : 931-937, 2015

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2024 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2021-01-01 평가 등재학술지 선정 (해외등재 학술지 평가) KCI등재
      2020-12-01 평가 등재후보로 하락 (해외등재 학술지 평가) KCI등재후보
      2010-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2008-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2005-05-27 학술지명변경 한글명 : 대한암학회지 -> Cancer Research and Treatment KCI등재
      2005-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2004-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2002-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 3.58 0.89 3.01
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      2.62 2.28 1.846 0.26
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼